Fundus Autofluorescence Changes After Ranibizumab Treatment for Subfoveal Choroidal Neovascularization Secondary to Pathologic Myopia.
OBJECTIVE
To describe fundus autofluorescence (FAF) patterns of myopic choroidal neovascularization (CNV) treated with intravitreal ranibizumab and their correlation with visual acuity.


METHODS
Prospective interventional case series.


METHODS
Twenty-seven eyes (27 patients) affected by myopic CNV were enrolled from January 2011 to January 2013. All patients underwent a complete ophthalmologic examination, including best-corrected visual acuity (BCVA) determination and fundus autofluorescence (FAF). The patients underwent ranibizumab injections following a pro re nata treatment regimen. The main outcome measure was the identification of the FAF patterns of myopic CNV over a 12-month follow-up. The secondary outcome was the correlation of the FAF patterns with the BCVA.


RESULTS
At baseline 17 eyes (63%) showed a hyperautofluorescent pattern and 10 eyes (37%) a patchy pattern. BCVA changed from 0.48 ± 0.23 (logMAR) to 0.30 ± 0.32 at the 12-month examination (P = .027) in the hyper-FAF subgroup. In the subgroup showing the patchy pattern, the BCVA declined slightly from 0.51 ± 0.27 to 0.56 ± 0.37 (P = .53). The 14 eyes preserving the hyper-FAF pattern during the follow-up had a final BCVA of 0.20 ± 0.17, whereas the 9 eyes maintaining the patchy pattern showed a final BCVA of 0.60 ± 0.37 (P = .002). The atrophic area of the retinal pigment epithelium assessed on the basis of FAF increased from 1.27 ± 2.80 mm(2) to 1.83 ± 3.74 mm(2) at the 12-month examination (P = .016). The mean atrophic area increased by 0.37 mm(2) in the hyper-FAF subgroup and by 0.90 mm(2) in the patchy FAF subgroup.


CONCLUSIONS
Two main patterns were identified on FAF in myopic CNV and were related to the prognostic evolution, the hyperautofluorescent CNV being associated with a greater visual gain and fewer atrophic changes over a 12-month follow-up.
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
Maurizio Battaglia
MB
Parodi
Fondazione G.B. Bietti per l'Oftalmologia, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Rome, Italy. Electronic address: pierluigi.iacono@libero.it.
Pierluigi
P
Iacono
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
Riccardo
R
Sacconi
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
Lorenzo
L
Iuliano
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
Francesco
F
Bandello
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D002829:Choroid / Q000187:drug effects / Q000473:pathology; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000175:diagnosis; D011379:Prognosis; D011446:Prospective Studies; D000069579:Ranibizumab; D055213:Retinal Pigment Epithelium / Q000187:drug effects / Q000473:pathology*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab